News

The public entity has remained closed since 2011 after it incurred massive losses, the The Himalayan Times reported. The company had reported a cumulative loss of NPR485.85m ($6.64m)

The core technology is based on a novel antimicrobial targeting paradigm. The platform identifies and targets discrete amino acid insertion or deletion differences between essential homologous proteins that

The facility will manufacture the Ming Che product line of tailor-made lab water purification systems and consumables which will be sold exclusively in China. The products will cater

The European Medicines Agency’s (EMA) acceptance of the marketing authorization application (MAA) of peginesatide has triggered the milestone. Peginesatide, indicated to treat anemia associated with chronic kidney disease

Azul Instant is an all-natural supplement for erectile dysfunction (ED) developed by the comoany as an alternative to prescription drugs. The product carries no side effects, the company

The non-exclusive license agreement covers the delivery of multiple Slonomics-based DNA libraries. As per the agreement, MorphoSys will receive committed annual funding for the delivery of libraries and

TAK-875 is a selective agonist of GPR40, one of the GPCRs that are expressed in pancreatic islet cells. The Phase 2 trial is a randomized double-blind placebo- and

Quintiles and RVC Biofund collaborate to address Russia’s healthcare initiatives in accordance with its Healthcare 2020 Development Program. This will include implementing best practices to support medical science

These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications, the